IL6 and heart failure: Nonetheless, ongoing phase 3 trials, such as HERMES and ATHENA, are ongoing to evaluate IL-6 inhibition with ziltivekimab and may clarify whether more targeted approaches can provide clinical benefit in the heart failure scenario.